Reviews/Polyphenols and Antioxidants/Resveratrol and glycaemic control type 2 diabetes
Met · POLY-MET-03 · v2
Borderline: within 4 points of the Uncertain/Doubtful boundary, so a re-grade could land either side.
Several placebo-controlled trials in people with type 2 diabetes find that resveratrol lowers fasting blood sugar and measures of insulin resistance [1], [9], [11], and one short trial reported improvements against its own starting point [6]. But the largest and longest trial, with 192 patients over six months, found no effect on any sugar measure [8], and a crossover trial reached the same null result [2]. Crucially, HbA1c, the standard long-term measure of blood-sugar control, barely moves anywhere in this evidence. The benefit that does appear is confined to fasting glucose and a related calculation, not to the measure that defines glycaemic control. Because strong, well-run trials point in opposite directions and the key marker is unchanged, the panel concluded the evidence cannot settle whether resveratrol genuinely improves glycaemic control.
Among T2DM patients, placebo-controlled trials report significant between-group reductions in fasting glucose and insulin resistance at 200 mg/day over 24 weeks [1], 500 mg/day over 4 weeks [9], and 800 mg/day over 8 weeks [11], with within-baseline reductions at 1 g/day over 45 days [6]. Against these, the largest trial (192 patients, 500 or 40 mg/day, 6 months) found no difference in fasting glucose, glycated haemoglobin or insulin [8], a 5-week crossover trial found no effect on glucose or HbA1c [2], and [7] and [5] reported no significant glycaemic effect. HbA1c is null where reported [8], [2], [5] and is not among the significant reductions in [1]. The positive signal therefore sits in fasting glucose and HOMA-IR rather than HbA1c. The contested point: The corpus divides on whether a real effect exists at all: positive fasting-glucose trials [1], [9], [11] sit directly against the best-powered null trial [8] and the crossover null [2]. It further divides on what is being improved, since fasting glucose falls in some trials while HbA1c, the defining marker of glycaemic control, stays unmoved across [8], [2], [5] and [1].
All 13 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Polyphenols and Antioxidants, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The corpus is internally conflicting: the largest and longest trial [8] (n=192, 6 mo) and the crossover trial [2] find no glycaemic effect, directly contradicting the positive trials. A claim of improvement cannot be sustained when well-powered evidence is null.
HbA1c, the standard measure of glycaemic control, is essentially unmoved: null in [8], [2] and [5], and absent from the significant-reduction list in [1] despite being measured. The positive signal is confined to fasting glucose and HOMA-IR surrogates, so the claim overreaches 'glycaemic control'.
Where it remains uncertain. The largest, longest trial found no glycaemic effect [8], the crossover trial agreed [2], and HbA1c did not move where measured [8], [2], [5], [1].
Aleatory
Several trials are small (n=14 [2], n=45 [11], n=56 [9]), so between-patient variation can drive apparent effects either way.
Epistemic
The defining marker of glycaemic control is null where reported [8], [2], [5] and absent from the significant list in [1], leaving durable control unestablished.
Inferential
[6]'s reductions are reported 'when compared to their baseline levels', a within-group rather than placebo-controlled comparison, weakening causal inference.
The load-bearing papers from a corpus of 13, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Supports: between-group reduction in glucose, insulin and HOMA-IR over 24 wk in T2DM
“The resveratrol supplementation after 24 weeks was resulted in significant reduction [mean difference (95%CI)] of plasma glucose[- 0.50(-0.94 to -0.06)], insulin[- 1.31(-2.24 to -0.38)], homeostatic model assessment of insulin resistance[- 0.83(-1.37 to -0.29)]”
Panel auditInternal validity: high · scope of inference: T2D patients on oral hypoglycaemic drugs taking 200 mg/day resveratrol for 24 weeks.Key limitations: add-on to existing oral hypoglycaemics · 16/110 did not complete · single centre
Refutes: no effect on glycaemic control in crossover RCT
“5 wk of twice-daily 500 mg-resveratrol supplementation had no effect on GLP-1 secretion, glycemic control, gastric emptying, body weight, or energy intake. Our observations do not support the use of resveratrol for improving glycemic control”
Panel auditInternal validity: medium · scope of inference: Diet-controlled T2D with near-normal HbA1c (6.4%) over 5 weeks.Key limitations: very small sample · short duration · well-controlled low-HbA1c population leaves little room to improve
Refutes: largest, longest trial finds no glycaemic benefit
“We failed to detect significant differences in weight, BMI, waist circumference, and values of arterial blood pressure, fasting glucose, glycated hemoglobin, insulin, C-peptide, free fatty acids”
Panel auditInternal validity: high · scope of inference: T2D patients taking 40 or 500 mg/day resveratrol for 6 months.Key limitations: subgroup CRP findings are exploratory · total cholesterol/triglycerides slightly rose in 500 mg arm
Refutes: no effect on glucose or HbA1c over 1 yr (low-dose extract)
“supplementation with GE or GE-RES did not affect body weight, blood pressure, glucose, HbA1c or lipids, beyond the values regulated by gold standard medication in these patients”
Panel auditInternal validity: medium · scope of inference: Medicated hypertensive T2D men with coronary artery disease over 12 months of low-dose (8 mg) resveratrol-containing grape extract.Key limitations: low resveratrol dose within a grape extract · patients already well-controlled on medication (floor effect) · sample size not reported
4 of 13 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Genuinely conflicting primary evidence with the best-powered trial null and the definitive marker HbA1c unchanged keeps this at the lower edge of Uncertain.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
HbA1c as primary endpoint. The positive signal is confined to fasting glucose and HOMA-IR, while HbA1c is unmoved [8], [2], [5], so the claim of 'glycaemic control' is not demonstrated on its defining marker. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An adequately powered RCT of at least 3-6 months with HbA1c as the pre-specified primary endpoint in T2DM patients.
Open question: Does resveratrol produce a between-group reduction in HbA1c in type 2 diabetes? Why it is still open: HbA1c is null in [8], [2] and [5] and absent from the significant reductions in [1] despite being measured, so no corpus trial shows it moving versus placebo.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19